Vitamin B12 manufacturer HealthTech BioActives (HTBA) has completed a €25m modernisation project of its Spanish R&D and manufacturing facility in Murcia.
Through this investment, HTBA has constructed a novel production plant, making it the first company in Europe capable of producing every active form of vitamin B12.
The project also introduced advanced manufacturing processes, optimising the company's ability to produce citrus flavonoids and vitamin B12 in a rapid and reliable manner.
On top of the new plant, HTBA has invested into its current capabilities by upgrading its citrus flavonoid production plant.
By investing in its capabilities, the company will be able to further develop its patented manufacturing process for diosmin — a specialist flavonoid that promotes cardiovascular health.
Via this investment, HTBA has become the only company globally that can manufacture diosmin without using artificial solvents.
"Our origins in citrus flavonoids and vitamin B12 date back more than 45 years and this innovation project marks a huge milestone for HTBA," notes CEO of HTBA, Alexandre Valls-Coma.
“Through this significant investment, we’re not only reinforcing our global leadership in the production of active forms of vitamin B12 and citrus flavonoids, but we’re also furthering our commitment to upholding the highest standards in sustainability and innovation."
Considering sustainability
In light of the current climate crisis, HTBA has also enhanced the sustainability credentials of the Murcia site, ensuring that the novel automation systems and technologies installed can be powered on renewable energy.
They have also found new ways to optimise resource consumption, enabling 98% of the waste generated in the production process to be recovered, revalued or recycled.